Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history.

Achondroplasia Cervicomedullary decompression Fibroblast growth factor receptor 3 (FGFR3) Foramen magnum stenosis Genu varum Natural history Skeletal dysplasia

Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
05 2021
Historique:
received: 13 09 2020
revised: 24 01 2021
accepted: 30 01 2021
pubmed: 6 2 2021
medline: 9 7 2021
entrez: 5 2 2021
Statut: ppublish

Résumé

Achondroplasia, the most common form of disproportionate short stature, is caused by a variant in the fibroblast growth factor receptor 3 (FGFR3) gene. Advances in drug treatment for achondroplasia have underscored the need to better understand the natural history of this condition. This article provides a critical review and discussion of the natural history of achondroplasia based on current literature evidence and the perspectives of clinicians with extensive knowledge and practical experience in managing individuals with this diagnosis. This review draws evidence from recent and ongoing longitudinal natural history studies, supplemented with relevant cross-sectional studies where longitudinal research is lacking, to summarize the current knowledge on the nature, incidence, chronology, and interrelationships of achondroplasia-related comorbidities across the lifespan. When possible, data related to adults are presented separately from data specific to children and adolescents. Gaps in knowledge regarding clinical care are identified and areas for future research are recommended and discussed.

Identifiants

pubmed: 33545406
pii: S8756-3282(21)00034-X
doi: 10.1016/j.bone.2021.115872
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115872

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Julie Hoover-Fong (J)

McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: jhoover2@jhmi.edu.

Moira S Cheung (MS)

Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, UK.

Virginia Fano (V)

Department of Growth and Development, Hospital Garrahan, Buenos Aires, Argentina.

Lars Hagenas (L)

Karolinska Institute, Division of Pediatric Endocrinology, Department of Women's and Children's Health, Stockholm, Sweden.

Jacqueline T Hecht (JT)

University of Texas, Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, USA.

Penny Ireland (P)

Queensland Paediatric Rehabilitation Service, Queensland Children's Hospital, Brisbane, Queensland, Australia.

Melita Irving (M)

Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, UK.

Klaus Mohnike (K)

Otto-von-Guericke-University Magdeburg, Department of Pediatrics, Magdeburg, Germany.

Amaka C Offiah (AC)

Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK.

Ericka Okenfuss (E)

Kaiser Permanente - Sacramento Medical Center, Department of Genetics, Sacramento, CA, USA.

Keiichi Ozono (K)

Osaka University Graduate School of Medicine, Department of Pediatrics, Osaka, Japan.

Cathleen Raggio (C)

Hospital for Special Surgery, Pediatric Orthopedic Surgery Service, New York, NY, USA.

Louise Tofts (L)

Kids Rehab, The Children's Hospital at Westmead, Westmead, NSW, Australia.

Dominique Kelly (D)

BioMarin Pharmaceutical Inc., Global Medical Affairs, Novato, CA, USA.

Renée Shediac (R)

BioMarin Pharmaceutical Inc., Global Medical Affairs, Novato, CA, USA.

Wayne Pan (W)

BioMarin Pharmaceutical Inc., Global Medical Affairs, Novato, CA, USA.

Ravi Savarirayan (R)

Murdoch Children's Research Institute, Royal Children's Hospital, University of Melbourne, Parkville, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH